BBIOBridgeBio Pharma Inc
BBIO
BridgeBio Pharma Inc5,394
Mkt Cap
$13.41BVolume
3.05M52W High
$84.9452W Low
$34.13PE Ratio
-17.69BBIO Fundamentals
Price
$66.26Prev Close
$68.45Open
$67.9650D MA
$70.97Beta
1.30Avg. Volume
2.49MEPS (Annual)
-$3.79P/B
-5.69Rev/Employee
$598,421.93$16,800.66
Futures Rise, US Stocks Set For New Record As Hopes For Iran Peace Deal Persist Despite Bombing
Futures Rise, US Stocks Set For New Record As Hopes For Iran Peace Deal Persist Despite Bombing
US futures are higher again, led by tech and small caps. As of 7:30am, S&P 500 futures rose 0.7%, signaling US stocks are set for another record high when the market reopens after Memorial...
Zero Hedge
BioMarin's Voxzogo Meets Goal in Late-Stage Study for Hypochondroplasia
BMRN's shares rise after Voxzogo hits the main goal in a late-stage hypochondroplasia study, supporting planned FDA filings in 2026.
Zacks
Wall Street's Cardiac Bet: Where Diagnostics Meet the Money
Wall Street's Cardiac Bet: Where Diagnostics Meet the Money Wall Street's Cardiac Bet: Where Diagnostics Meet the Money PR Newswire VANCOUVER, BC, May 12, 2026 ISSUED ON BEHALF OF VENTRIPOINT DIAGNOSTICS LTD.USANewsGroup.com News CommentaryVANCOUVER, BC, May 12, 2026 /PRNewswire/ --Cardiovascular...
PR Newswire
BridgeBio Pharma (BBIO) Reports Q1 Loss, Tops Revenue Estimates
BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -19.32% and +8.19%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Gartner Gears Up to Report Q1 Earnings: What's in the Offing?
IT heads into Q1 earnings release, with a slight top-line dip expected, as Conferences growth helps offset softer Insights and Consulting trends.
Zacks
IQVIA Set to Report Q1 Earnings: Here's What You Should Know
IQV heads into Q1 earnings release with steady growth expectations, driven by AI-backed solutions, strong bookings and rising pharma demand.
Zacks
Vanguard Group Inc. Increases Stake in BridgeBio Pharma, Inc. $BBIO
Vanguard Group Inc. grew its position in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 0.2% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 16,862,691 shares of the company's stock after buying an additional 30,632 shares...
MarketBeat
Amphastar Pharmaceuticals (AMPH) Expected to Beat Earnings Estimates: Should You Buy?
Amphastar (AMPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
Truist Financial Issues Positive Forecast for BridgeBio Pharma (NASDAQ:BBIO) Stock Price
Truist Financial boosted their target price on BridgeBio Pharma from $95.00 to $102.00 and gave the stock a "buy" rating in a research report on Wednesday...
MarketBeat
BridgeBio Pharma, Inc. $BBIO Holdings Lifted by Moody Aldrich Partners LLC
Moody Aldrich Partners LLC raised its holdings in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 83.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 131,184 shares of the company's stock after purcha...
MarketBeat
<
1
2
...
>
Compact View
Not available
Not available